搜索
阿尔尼拉姆制药公司
ALNY添加自选
278.090USD
-4.630-1.64%
收盘 06/18, 16:00（美东）报价延迟15分钟
36.81B总市值
68.06市盈率 TTM
关于 阿尔尼拉姆制药公司 公司
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
阿尔尼拉姆制药公司简介
公司代码ALNY
公司名称Alnylam Pharmaceuticals Inc
上市日期May 28, 2004
CEOGreenstreet (Yvonne L)
员工数量2230
证券类型Ordinary Share
年结日May 28
公司地址675 W Kendall St
城市CAMBRIDGE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编02142-1168
电话16175518200
网址https://www.alnylam.com/
公司代码ALNY
上市日期May 28, 2004
CEOGreenstreet (Yvonne L)
阿尔尼拉姆制药公司公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.38K
+7.29%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
39.68K
+0.24%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
15.33K
+5.62%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.31K
+15.58%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
807.00
+83.15%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
671.00
--
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
671.00
--
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Pushkal P. Garg, M.D.
Dr. Pushkal P. Garg, M.D.
Executive Vice President, Chief Research and Development Officer
Executive Vice President, Chief Research and Development Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.38K
+7.29%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
39.68K
+0.24%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
15.33K
+5.62%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.31K
+15.58%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
807.00
+83.15%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
671.00
--
常见问题
阿尔尼拉姆制药公司的前五大股东是谁？
阿尔尼拉姆制药公司 的前五大股东如下：Dr. Yvonne L. Greenstreet, M.D.
有多少机构持有阿尔尼拉姆制药公司(ALNY)的股份？
截至2026Q1，共有1634家机构持有阿尔尼拉姆制药公司的股份，合计持有的股份价值约为133.66M，占公司总股份的100.11%。与2025Q4相比，机构持股有所增加，增幅为-6052832.00。
哪个业务部门对阿尔尼拉姆制药公司的收入贡献最大？
在2026Q1，AMVUTTRA业务部门对阿尔尼拉姆制药公司的收入贡献最大，创收2.31B，占总收入的62.30%。
